Editas Medicine, Inc. (EDIT) income statement
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/309% above fair value
$1.77−0.05 (-3.01%)
Close on Nov 18, 2026Market cap $271.84MP/E –Yield –
Editas Medicine, Inc. financial ratios
See a number that looks wrong?